Illinois Municipal Retirement Fund raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 72.6% in the 3rd quarter, HoldingsChannel reports. The fund owned 13,818 shares of the company’s stock after buying an additional 5,812 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Axsome Therapeutics were worth $2,548,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of AXSM. BlackRock Inc. acquired a new position in shares of Axsome Therapeutics during the second quarter worth approximately $759,695,000. First Trust Advisors LP grew its stake in shares of Axsome Therapeutics by 1,230.2% during the first quarter. First Trust Advisors LP now owns 577,479 shares of the company’s stock valued at $97,606,000 after purchasing an additional 534,066 shares during the last quarter. Bank of America Corp DE bought a new stake in shares of Axsome Therapeutics during the second quarter valued at approximately $110,756,000. Canada Pension Plan Investment Board bought a new stake in shares of Axsome Therapeutics during the second quarter valued at approximately $55,171,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $48,275,000. 81.49% of the stock is owned by institutional investors.
Axsome Therapeutics Trading Down 1.9%
Shares of NASDAQ AXSM traded down $2.68 during mid-day trading on Friday, hitting $141.69. The company’s stock had a trading volume of 972,544 shares, compared to its average volume of 1,136,376. The stock has a market cap of $7.45 billion, a price-to-earnings ratio of -46.30 and a beta of 0.86. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.42 and a quick ratio of 1.34. Axsome Therapeutics, Inc. has a one year low of $123.00 and a one year high of $260.19. The company’s fifty day simple moving average is $171.45 and its 200-day simple moving average is $196.75.
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.38. The company had revenue of $259.69 million during the quarter, compared to analysts’ expectations of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. Axsome Therapeutics’s revenue was up 51.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.94) EPS. On average, sell-side analysts anticipate that Axsome Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several research analysts recently weighed in on AXSM shares. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Thursday, October 15th. Piper Sandler reduced their price objective on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating on the stock in a report on Monday, October 26th. Royal Bank Of Canada decreased their price objective on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 3rd. Wells Fargo & Company reissued an “outperform” rating on shares of Axsome Therapeutics in a research note on Tuesday, November 3rd. Finally, Mizuho dropped their target price on Axsome Therapeutics from $284.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $266.21.
Get Our Latest Stock Analysis on AXSM
Insider Transactions at Axsome Therapeutics
In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total value of $2,086,500.00. Following the transaction, the chief operating officer directly owned 10,000 shares of the company’s stock, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.60% of the company’s stock.
Axsome Therapeutics Company Profile
Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
Featured Articles
- Five stocks we like better than Axsome Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding AXSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report).
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
